Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon

AIDS Research and Human Retroviruses

Volumn 24, Issue 6, 2008, Pages 781-785

  Turriziani, Ombretta ^a   Russo, Gianluca ^a   Lichtner, Miriam ^a   Stano, Armando ^a   Tsague, Giselle ^b   Maida, Paola ^a   Vullo, Vincenzo ^a   Antonelli, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Dschang Hospital District   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADOLESCENT; ADULT; ARTICLE; BABY; CAMEROON; CHILD; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; NEWBORN; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; RURAL AREA; SEQUENCE ANALYSIS; SINGLE DRUG DOSE; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS TYPING;

ADULT; ANTI-HIV AGENTS; CAMEROON; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; NEVIRAPINE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMORPHISM, GENETIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RNA, VIRAL; RURAL HEALTH; SEQUENCE ANALYSIS, RNA;

EID: 45749131052     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0213     Document Type: Article

References (26)

1. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, Learn GH, Leitner T, McCutchan F, Osmanov S,Peeters M, Pieniazek D, Salminen M, Sharp PM, Wolinsky S, and Korber B: HIV-1 nomenclature proposal. Science 2000;288:55-56.
2. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, and Delaporte E: Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000;38:3919-3925.
3. Kantor R and Katzenstein D: Polymorphism in HIV-1 nonsubtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003;5:25-35.
4. Vessiere A, Nerrienet E, Kfutwah A, Menu E, Tejiokem M, Pinson-Recordon P, Barre-Sinoussi F, Fleury H, and Ayouba A: HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naïve pregnant women in Yaounde, Cameroon. J Acquir Immune Defic Syndr 2006;42:256-258.
5. Koizumi Y, Ndembi N, Miyashita M, Lwembe R, Kageyama S, Mbanya D, Kaptue L, Numazaki K, Fujiyama Y, and Ichimura H: Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J Acquir Immune Defic Syndr 2006;43:15-22.
6. Konings FA, Haman GR, Xue Y, Urbanski MM, Hertzmark K, Nanfack A, Achkar JM, Burda ST, and Nyambi PN: Genetic analysis of HIV-1 strains in rural eastern Cameroon indicates the evolution of second-generation recombinants to circulating recombinant forms. J Acquir Immune Defic Syndr 2006;42:331-341.
7. Fonjungo PN, Mpoudi EN, Torimiro JN, Alemnji GA, Eno LT, Lyonga EJ, Nkengasong JN, Lal RB, Rayfield M, Kalish ML, Folks TM, and Pieniazek D: Human immunodeficiency virus type 1 group m protease in Cameroon: Genetic diversity and protease inhibitor mutational features. J Clin Microbiol 2002;40:837-845.
8. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Miro F, and Jackson JB: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-1957.
9. Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, Dhlamini P, Puren A, Bhayroo S, Steyn J, and McIntyre JA: Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007;44:148-153.
10. Toni TD, Masquelier B, Lazaro E, Dore-Mbami M, Ba-Gomis FO, Tea-Diop Y, Kouakou K, Diby J, Sia E, Soppi S, Essien S, Schrive MH, Pinson P, Chenal H, and Fleury HJ: Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Cote d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. AIDS Res Hum Retroviruses 2005;21:1031-1034.
11. Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, Mellors J, Morris L, and Coffin J: Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 2006;103:7094-7099.
12. Diallo K, Gotte M, and Wainberg MA: Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2003;47:3377-3383.
13. Wainberg MA: The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther 2004;2:147-151.
14. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, and Wainberg MA: Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002;6:1753-1761.
15. Chan KC, Galli RA, Montaner JS, and Harrigan PR: Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection. AIDS 2003;17:1256-1258.
16. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, Segal MR, Petropoulos CJ, and Grant RM: Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004;18:1683-1689.
17. Konings FA and Nyambi PN: V118I substitution in the reverse transcriptase gene of HIV type 1 CRF02_AG strains infecting drug-naive individuals in Cameroon. AIDS Res Hum Retroviruses 2004;20:673-678.
18. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, and Richman DD: Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006;14:125-130.
19. Zaccarelli M, Tozzi V, Lorenzini P, Forbici F, Narciso P, Ceccherini-Silberstein F, Trotta MP, Bertoli A, Liuzzi G, Marconi P, Mosti S, Perno CF, and Antinori A: The V118I mutation as a marker of advanced HIV infection and disease progression. Antiviral Ther 2007;12:163-168.
20. Vergne L, Stuyver L, Van Houtte M, Butel C, Delaporte E, and Peeters M: Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naïve patients. J Clin Virol 2006;36:43-49.
21. Holguin A, Paxinos E, Hertogs K, Womac C, and Soriano V: Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 2004;31:215-220.
22. Holguin A, Alvarez A, and Soriano V: High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS 2002;16:1163-1170.
23. Montes B, Vergne L, Peeters M, Reynes J, Delaporte E, and Segondy M: Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr 2004;35:329-336.
24. Deshpande A, Recordon-Pinson P, Deshmukh R, Faure M, Jauvin V, Garrigue I, Lafon ME, and Fleury HJ: Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations. AIDS Res Hum Retroviruses 2004;20:1032-1035.
25. Erickson JW, Gulnik SV, and Markowitz M: Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 1999;13:S189-204.
26. Hoffman CJ and Gallant JE: When and how to use tipranavir and darunavir. AIDS Read 2007;17:194-201.